Keith Coleman
About Keith Coleman
Keith Coleman is the Associate Director of CMC Strategy at Bristol Myers Squibb, with over 15 years of experience in the pharmaceutical industry, specializing in analytical science and technology.
Current Role at Bristol Myers Squibb
Keith Coleman holds the position of Associate Director - CMC Strategy at Bristol Myers Squibb, where he has been instrumental since November 2020. In this role, he focuses on the development and implementation of critical CMC (Chemistry, Manufacturing, and Controls) strategies, contributing significantly to the company's operational success in ensuring the proper manufacturing and quality control of their pharmaceutical products.
Career at Bristol Myers Squibb
Before assuming his current role, Keith Coleman served in various capacities at Bristol Myers Squibb. From 2018 to 2020, he worked as Associate Director of Analytical Science & Technology in Cruiserath. Prior to that, he was the Analytical Science & Technology Manager from 2016 to 2018 at the Cruiserath Blanchardstown site. His tenure at Bristol Myers Squibb exemplifies his steady progression through leadership roles, highlighting his expertise in analytical science and technology.
Previous Experience at Pfizer
Keith Coleman has extensive experience from his time at Pfizer. He began as a Chemistry Analyst in 2006, eventually rising to the position of Development Team Lead by 2015. His roles at Pfizer included being an Analytical Scientist, Senior Scientist, and finally, a Development Team Lead in Grange Castle from 2015 to 2016. This period reflects his growing responsibilities and expertise in pharmaceutical development and analysis.
Educational Background
Keith Coleman has a robust educational background with several diplomas and degrees. He earned a Bachelor's of Science Double Honours in Chemistry and Biology from the National University of Ireland, Maynooth, followed by a Master of Science in Pharmaceutical Analysis from Trinity College, Dublin. He also acquired a Diploma in Project Management from Griffith College Dublin and a Diploma in Management Studies from Dublin Business School. This education supports his extensive and varied career in the pharmaceutical industry.
Early Career and Transition
Keith Coleman began his career at Rottapharm | Madaus Portugal in Quality Control, where he spent one year before transitioning to Pfizer. His move from quality control to progressively senior analytical roles demonstrates a steady career growth and adaptation to different facets of the pharmaceutical industry. This early stage of his career set a strong foundation for his later achievements at both Pfizer and Bristol Myers Squibb.